恩瑞格的治疗效果怎么样？

Thalassemia is also called thalassemia. There are about 300,000 patients with thalassemia major and intermedia in my country. Blood transfusion is the mainstay of treatment for thalassemia major and intermedia. In addition, blood transfusion is also the main maintenance therapy for myelodysplastic syndrome (MDS). There are about 300,000 new MDS patients in my country every year. In addition, blood transfusion is also the main maintenance therapy for myelodysplastic syndrome (MDS). Long-term blood transfusion can easily lead to secondary iron overload. Iron overload refers to the pathological phenomenon of excessive iron deposition in human tissues and organs, leading to cell damage and organ dysfunction. Iron overload can cause damage to cardiovascular, endocrine, liver, kidney, nervous system, etc., leading to various diseases and serious harm. Iron chelators can effectively increase iron excretion, reduce iron content in the body and its pathological deposition in various organs. They are currently the only effective drugs for the treatment of iron overload.

So, what is the therapeutic effect of Enrig?

Objective: To explore the clinical efficacy of Enrig and deferoxamine in the treatment of children with iron overload in β-thalassemia major.

Methods: 47 children with iron overload of β-thalassemia major were collected and divided into two groups according to different treatment plans: 26 cases in the observation group were treated with Enriga, and 21 cases in the control group were treated with deferoxamine.

After 12 months of treatment, the therapeutic effects, serum ferritin (SF), adverse reactions, and heart and liver magnetic resonance imaging (MRI) T2 results of the two groups of children were compared.

After 12 months of treatment, there was no statistically significant difference in the total effective rate between the two groups (P>0.05); the total control rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05); the heart and liver T2 values of the observation group were significantly higher than those of the control group, and the difference was statistically significant (P<0.05). Scientific significance (P<0.05); the SF level of the observation group was significantly lower than that of the control group after 12 months of treatment, and the difference was statistically significant (P<0.05); the incidence of adverse reactions in the observation group was significantly lower than that of the control group, and the difference was statistically significant (P<0.05).

Conclusion: The short-term effect of treating iron overload in β-thalassemia major is significantly better than that of deferoxamine, which significantly reduces SF levels, especially the effect of iron removal in the liver, and reduces the occurrence of adverse reactions, which deserves clinical attention.